Development of a novel cell-based assay to diagnose recurrent focal segmental glomerulosclerosis patients

Pankaj Srivastava, Ashish K. Solanki, Ehtesham Arif, Bethany J. Wolf, Michael G. Janech, Milos N. Budisavljevic, Sang Ho Kwon, Deepak Nihalani

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Definitive diagnosis of glomerular disease requires a kidney biopsy, an invasive procedure that may not be safe or feasible to perform in all patients. We developed a noninvasive, accurate, and economical diagnostic assay with easy commercial adaptability to detect recurrent focal segmental glomerulosclerosis (rFSGS) after kidney transplant. Since FSGS involves podocyte damage and death, our approach involved mRNA profiling of cultured podocytes treated with plasma from patients with rFSGS to identify upregulated genes involved in podocyte damage. For concept validation, three upregulated pro-apoptotic candidate genes (IL1β, BMF, and IGFBP3) were selected, and their promoter regions were cloned into a luciferase-based reporter vector and transfected into podocytes to generate stable podocyte cell lines. Strikingly, when exposed to rFSGS patient plasma, these cell lines showed increased reporter activity; in contrast, no reporter activity was noted with plasma from patients with non-recurrent FSGS or membranous nephropathy. Area under the receiver operating characteristics curves (AUCs) for models discriminating between rFSGS and other nephropathies (non-recurrent FSGS and membranous nephropathy) and between rFSGS and non-recurrent FSGS ranged from 0.81 to 0.86, respectively. Estimated sensitivities and specificities for the diagnosis of rFSGS were greater than 80% for the IL1β and BMF cell lines, and were slightly lower for the IGFBP3 cell line. Importantly, the novel approach outlined here for the diagnosis of rFSGS is widely applicable to the design of sensitive and specific diagnostic/prognostic assays for other glomerular diseases.

Original languageEnglish (US)
Pages (from-to)708-716
Number of pages9
JournalKidney International
Volume95
Issue number3
DOIs
StatePublished - Mar 2019

Fingerprint

Focal Segmental Glomerulosclerosis
Podocytes
Cell Line
Membranous Glomerulonephritis
Kidney
Plasma Cells
Luciferases
Genetic Promoter Regions
ROC Curve
Genes
Area Under Curve
Transplants
Biopsy
Sensitivity and Specificity
Messenger RNA

Keywords

  • diagnosis
  • kidney
  • luciferase
  • podocytes
  • promoter
  • rFSGS
  • RNA-Seq

ASJC Scopus subject areas

  • Nephrology

Cite this

Srivastava, P., Solanki, A. K., Arif, E., Wolf, B. J., Janech, M. G., Budisavljevic, M. N., ... Nihalani, D. (2019). Development of a novel cell-based assay to diagnose recurrent focal segmental glomerulosclerosis patients. Kidney International, 95(3), 708-716. https://doi.org/10.1016/j.kint.2018.10.030

Development of a novel cell-based assay to diagnose recurrent focal segmental glomerulosclerosis patients. / Srivastava, Pankaj; Solanki, Ashish K.; Arif, Ehtesham; Wolf, Bethany J.; Janech, Michael G.; Budisavljevic, Milos N.; Kwon, Sang Ho; Nihalani, Deepak.

In: Kidney International, Vol. 95, No. 3, 03.2019, p. 708-716.

Research output: Contribution to journalArticle

Srivastava, P, Solanki, AK, Arif, E, Wolf, BJ, Janech, MG, Budisavljevic, MN, Kwon, SH & Nihalani, D 2019, 'Development of a novel cell-based assay to diagnose recurrent focal segmental glomerulosclerosis patients', Kidney International, vol. 95, no. 3, pp. 708-716. https://doi.org/10.1016/j.kint.2018.10.030
Srivastava, Pankaj ; Solanki, Ashish K. ; Arif, Ehtesham ; Wolf, Bethany J. ; Janech, Michael G. ; Budisavljevic, Milos N. ; Kwon, Sang Ho ; Nihalani, Deepak. / Development of a novel cell-based assay to diagnose recurrent focal segmental glomerulosclerosis patients. In: Kidney International. 2019 ; Vol. 95, No. 3. pp. 708-716.
@article{6df55dfbc8f74a7baf33e3b0d3389a89,
title = "Development of a novel cell-based assay to diagnose recurrent focal segmental glomerulosclerosis patients",
abstract = "Definitive diagnosis of glomerular disease requires a kidney biopsy, an invasive procedure that may not be safe or feasible to perform in all patients. We developed a noninvasive, accurate, and economical diagnostic assay with easy commercial adaptability to detect recurrent focal segmental glomerulosclerosis (rFSGS) after kidney transplant. Since FSGS involves podocyte damage and death, our approach involved mRNA profiling of cultured podocytes treated with plasma from patients with rFSGS to identify upregulated genes involved in podocyte damage. For concept validation, three upregulated pro-apoptotic candidate genes (IL1β, BMF, and IGFBP3) were selected, and their promoter regions were cloned into a luciferase-based reporter vector and transfected into podocytes to generate stable podocyte cell lines. Strikingly, when exposed to rFSGS patient plasma, these cell lines showed increased reporter activity; in contrast, no reporter activity was noted with plasma from patients with non-recurrent FSGS or membranous nephropathy. Area under the receiver operating characteristics curves (AUCs) for models discriminating between rFSGS and other nephropathies (non-recurrent FSGS and membranous nephropathy) and between rFSGS and non-recurrent FSGS ranged from 0.81 to 0.86, respectively. Estimated sensitivities and specificities for the diagnosis of rFSGS were greater than 80{\%} for the IL1β and BMF cell lines, and were slightly lower for the IGFBP3 cell line. Importantly, the novel approach outlined here for the diagnosis of rFSGS is widely applicable to the design of sensitive and specific diagnostic/prognostic assays for other glomerular diseases.",
keywords = "diagnosis, kidney, luciferase, podocytes, promoter, rFSGS, RNA-Seq",
author = "Pankaj Srivastava and Solanki, {Ashish K.} and Ehtesham Arif and Wolf, {Bethany J.} and Janech, {Michael G.} and Budisavljevic, {Milos N.} and Kwon, {Sang Ho} and Deepak Nihalani",
year = "2019",
month = "3",
doi = "10.1016/j.kint.2018.10.030",
language = "English (US)",
volume = "95",
pages = "708--716",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Development of a novel cell-based assay to diagnose recurrent focal segmental glomerulosclerosis patients

AU - Srivastava, Pankaj

AU - Solanki, Ashish K.

AU - Arif, Ehtesham

AU - Wolf, Bethany J.

AU - Janech, Michael G.

AU - Budisavljevic, Milos N.

AU - Kwon, Sang Ho

AU - Nihalani, Deepak

PY - 2019/3

Y1 - 2019/3

N2 - Definitive diagnosis of glomerular disease requires a kidney biopsy, an invasive procedure that may not be safe or feasible to perform in all patients. We developed a noninvasive, accurate, and economical diagnostic assay with easy commercial adaptability to detect recurrent focal segmental glomerulosclerosis (rFSGS) after kidney transplant. Since FSGS involves podocyte damage and death, our approach involved mRNA profiling of cultured podocytes treated with plasma from patients with rFSGS to identify upregulated genes involved in podocyte damage. For concept validation, three upregulated pro-apoptotic candidate genes (IL1β, BMF, and IGFBP3) were selected, and their promoter regions were cloned into a luciferase-based reporter vector and transfected into podocytes to generate stable podocyte cell lines. Strikingly, when exposed to rFSGS patient plasma, these cell lines showed increased reporter activity; in contrast, no reporter activity was noted with plasma from patients with non-recurrent FSGS or membranous nephropathy. Area under the receiver operating characteristics curves (AUCs) for models discriminating between rFSGS and other nephropathies (non-recurrent FSGS and membranous nephropathy) and between rFSGS and non-recurrent FSGS ranged from 0.81 to 0.86, respectively. Estimated sensitivities and specificities for the diagnosis of rFSGS were greater than 80% for the IL1β and BMF cell lines, and were slightly lower for the IGFBP3 cell line. Importantly, the novel approach outlined here for the diagnosis of rFSGS is widely applicable to the design of sensitive and specific diagnostic/prognostic assays for other glomerular diseases.

AB - Definitive diagnosis of glomerular disease requires a kidney biopsy, an invasive procedure that may not be safe or feasible to perform in all patients. We developed a noninvasive, accurate, and economical diagnostic assay with easy commercial adaptability to detect recurrent focal segmental glomerulosclerosis (rFSGS) after kidney transplant. Since FSGS involves podocyte damage and death, our approach involved mRNA profiling of cultured podocytes treated with plasma from patients with rFSGS to identify upregulated genes involved in podocyte damage. For concept validation, three upregulated pro-apoptotic candidate genes (IL1β, BMF, and IGFBP3) were selected, and their promoter regions were cloned into a luciferase-based reporter vector and transfected into podocytes to generate stable podocyte cell lines. Strikingly, when exposed to rFSGS patient plasma, these cell lines showed increased reporter activity; in contrast, no reporter activity was noted with plasma from patients with non-recurrent FSGS or membranous nephropathy. Area under the receiver operating characteristics curves (AUCs) for models discriminating between rFSGS and other nephropathies (non-recurrent FSGS and membranous nephropathy) and between rFSGS and non-recurrent FSGS ranged from 0.81 to 0.86, respectively. Estimated sensitivities and specificities for the diagnosis of rFSGS were greater than 80% for the IL1β and BMF cell lines, and were slightly lower for the IGFBP3 cell line. Importantly, the novel approach outlined here for the diagnosis of rFSGS is widely applicable to the design of sensitive and specific diagnostic/prognostic assays for other glomerular diseases.

KW - diagnosis

KW - kidney

KW - luciferase

KW - podocytes

KW - promoter

KW - rFSGS

KW - RNA-Seq

UR - http://www.scopus.com/inward/record.url?scp=85061376235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061376235&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2018.10.030

DO - 10.1016/j.kint.2018.10.030

M3 - Article

C2 - 30709661

AN - SCOPUS:85061376235

VL - 95

SP - 708

EP - 716

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 3

ER -